GlobeNewswire: Baxano Surgical, Inc. Contains the last 10 of 147 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T13:32:05ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2014/11/13/683173/10108275/en/Baxano-Surgical-Inc-Announces-Termination-of-Its-Nasdaq-Listing.html?f=22&fvtc=4&fvtv=7432Baxano Surgical, Inc. Announces Termination of Its Nasdaq Listing2014-11-13T22:44:52Z<![CDATA[RALEIGH, N.C., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that it is terminating its listing on The Nasdaq Global Market as of the close of business on November 24, 2014. The company has previously received notices from Nasdaq that it has failed to maintain a minimum bid price of $1.00 per share. In light of its current financial condition, the company does not anticipate that it will be able to meet such minimums or continue to meet other Nasdaq listing standards in the future. In addition, the company has filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in order to facilitate a going concern sale of the company. Following the termination of its listing on Nasdaq, the company intends to terminate its public reporting obligations under the Exchange Act as soon as possible.]]>https://www.globenewswire.com/news-release/2014/11/13/682898/10108055/en/Baxano-Surgical-to-Sell-Product-Lines-Through-Voluntary-Chapter-11-Court-Supervised-Auction-Process.html?f=22&fvtc=4&fvtv=7432Baxano Surgical to Sell Product Lines Through Voluntary Chapter 11 Court Supervised Auction Process2014-11-13T12:30:00Z<![CDATA[DIP Financing to Support Baxano Surgical's Operations RALEIGH, N.C., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the Company has filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. The bankruptcy filing was effected in order to facilitate a going concern sale of the Baxano Surgical minimally invasive products under Section 363 of the Bankruptcy Code.]]>https://www.globenewswire.com/news-release/2014/09/25/668433/10099990/en/Baxano-Surgical-Completes-Financing-and-Continues-Streamlined-Business-Operations.html?f=22&fvtc=4&fvtv=7432Baxano Surgical Completes Financing and Continues Streamlined Business Operations2014-09-25T11:30:00Z<![CDATA[RALEIGH, N.C., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, announced that the Company has completed a recent subordinated convertible note financing of approximately $1.5 million to extend its cash runway. In connection with the financing, the Company has also streamlined its business to reduce its operating expenses while maintaining its commercial operations. ]]>https://www.globenewswire.com/news-release/2014/09/18/666892/10099124/en/Baxano-Surgical-to-Explore-Strategic-Alternatives-for-Its-MIS-Spine-Business.html?f=22&fvtc=4&fvtv=7432Baxano Surgical to Explore Strategic Alternatives for Its MIS Spine Business2014-09-18T11:30:00Z<![CDATA[RALEIGH, N.C., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the Company has engaged Houlihan Lokey as its financial advisor to advise it on potential strategic alternatives for the Company's business.]]>https://www.globenewswire.com/news-release/2014/09/12/665679/10098377/en/Baxano-Surgical-to-Train-35-Surgeons-on-Advanced-MIS-Techniques.html?f=22&fvtc=4&fvtv=7432Baxano Surgical to Train 35 Surgeons on Advanced MIS Techniques2014-09-12T11:30:00Z<![CDATA[RALEIGH, N.C., Sept. 12, 2014 (GLOBE NEWSWIRE) -- Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the Company is participating in an MIS-based training course hosted by the International Society for the Advancement of Spine Surgery (ISASS), and co-chaired by Anthony Yeung, MD and James J Yue, MD.]]>https://www.globenewswire.com/news-release/2014/08/05/656243/10093085/en/Baxano-Surgical-Inc-Reports-Operating-Results-for-the-Second-Quarter-of-2014-Issues-Third-Quarter-2014-Guidance.html?f=22&fvtc=4&fvtv=7432Baxano Surgical, Inc. Reports Operating Results for the Second Quarter of 2014, Issues Third Quarter 2014 Guidance2014-08-05T20:05:00Z<![CDATA[– Second quarter revenue of $4.7 million, representing year-over-year growth of 20.1% and sequential growth of 5.5% –]]>https://www.globenewswire.com/news-release/2014/08/05/656033/10092899/en/Baxano-Surgical-Inc-Announces-Two-New-Patents-for-VEO-Direct-Lateral-and-AxiaLIF-Minimally-Invasive-Interbody-Fusion-Systems.html?f=22&fvtc=4&fvtv=7432Baxano Surgical, Inc. Announces Two New Patents for VEO Direct Lateral and AxiaLIF Minimally Invasive Interbody Fusion Systems2014-08-05T11:30:00Z<![CDATA[RALEIGH, N.C., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the United States Patent and Trademark Office has issued two patents on key Baxano Surgical technologies, bringing the company's patent portfolio to 92 patents in the U.S.]]>https://www.globenewswire.com/news-release/2014/07/24/653138/10090871/en/Baxano-Surgical-Announces-Second-Quarter-2014-Earnings-Conference-Call-and-Webcast.html?f=22&fvtc=4&fvtv=7432Baxano Surgical Announces Second Quarter 2014 Earnings Conference Call and Webcast2014-07-24T11:30:00Z<![CDATA[RALEIGH, N.C., July 24, 2014 (GLOBE NEWSWIRE) -- Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that it will release second quarter 2014 financial results on Tuesday, August 5, 2014 after the market closes. Ken Reali, President and Chief Executive Officer and Tim Shannon, Chief Financial Officer, will then conduct a conference call at 4:30 pm ET to review the results.]]>https://www.globenewswire.com/news-release/2014/07/18/651798/10089964/en/Economic-Analysis-of-Minimally-Invasive-Spine-Fusion-Using-AxiaLIF-Accepted-for-Publication-in-the-Journal-of-Managed-Care-Medicine.html?f=22&fvtc=4&fvtv=7432Economic Analysis of Minimally Invasive Spine Fusion Using AxiaLIF Accepted for Publication in the Journal of Managed Care Medicine2014-07-18T11:30:00Z<![CDATA[RALEIGH, N.C., July 18, 2014 (GLOBE NEWSWIRE) -- Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the ]]>https://www.globenewswire.com/news-release/2014/06/30/647522/10087502/en/Baxano-Surgical-Announces-First-Clinical-Use-of-the-Avance-MIS-Pedicle-Screw-System.html?f=22&fvtc=4&fvtv=7432Baxano Surgical Announces First Clinical Use of the Avance MIS Pedicle Screw System2014-06-30T11:30:00Z<![CDATA[RALEIGH, N.C., June 30, 2014 (GLOBE NEWSWIRE) -- Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the first case utilizing the Avance™ MIS Pedicle Screw System was recently performed by Dr. Sameer Mathur in Cary, NC. The innovative design of Avance provides for an easy-to-use, percutaneous pedicle screw system that addresses single, complex and multi-level spinal pathologies with minimal tissue disruption and trauma. The Avance system will be in limited market release through the end of third quarter of 2014 and is planned for full launch in the fourth quarter of 2014.]]>